FOCUS UNIVERSAL INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FOCUS UNIVERSAL INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $255.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $398.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $440.5K | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $353.6K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.43M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.68M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $1.46M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $308.1K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $898.1K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $1.12M | Apr 2, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.3K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $59.7K | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $22.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $297.2K | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $283.8K | Mar 23, 2021 |
| FY2020 | Dec 31, 2019 | $118.2K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $170.2K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $171.8K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $255.4K | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.79M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.20M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.72M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.93M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.22M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.54M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($3.18M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($2.02M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($626.4K) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($467.4K) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.20M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.95M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($5.21M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.02M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.70M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($3.33M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($1.58M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($520.5K) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($467.0K) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $920.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.38M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.32M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $220.5K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $256.6K | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $255.2K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $221.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $208.2K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $201.9K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.10M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.66M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.53M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.96M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.97M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.96M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($1.70M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($1.41M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($445.7K) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($400.8K) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.1K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $18.7K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $20.6K | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $42.2K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $23.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.3K | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $11.1K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $4.60M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $8.2K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.89M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.08M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.33M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $9.32M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.02M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.59M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $7.23M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $9.28M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $490.5K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $485.7K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $366.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $885.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.79M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.57M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $899.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $788.7K | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $540.0K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $212.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $563.1K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $431.9K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.57M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.20M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $3.55M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $7.76M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $13.12M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $4.80M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $6.69M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $9.07M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | ($72.6K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $53.8K | Mar 11, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.02M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($25.78M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($22.58M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($17.86M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($12.94M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.72M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($7.18M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($4.00M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.98M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($1.35M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $394.4K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $340.1K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $832.0K | Mar 22, 2017 |
| FY2016 | Mar 31, 2015 | $78.0K | Mar 22, 2017 |
| FY2016 | Dec 31, 2014 | $136 | Mar 22, 2017 |
| FY2015 | Mar 31, 2014 | $7.4K | Jul 28, 2015 |
| FY2015 | Mar 31, 2013 | $0 | Jul 28, 2015 |
| FY2015 | Dec 3, 2012 | $0 | Jul 28, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 915,097 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 715,366 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 6.48M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 65.30M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 43.26M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 40.96M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 40.96M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 40.91M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 34.57M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | 34.57M | Apr 2, 2018 |